Related Experiment Video
Updated: Nov 9, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1
Thomas Kryza1, Tashbib Khan1, Scott Lovell2,3
1Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.
Abstract:
CUB domain-containing protein 1 (CDCP1) is an oncogenic orphan transmembrane receptor and a promising target for the detection and treatment of cancer. Extracellular proteolysis of CDCP1 by poorly defined mechanisms induces pro-metastatic signaling. We describe a new approach for the rapid identification of proteases responsible for key proteolytic events using a substrate-biased activity-based probe (sbABP) that incorporates a substrate cleavage motif grafted onto a peptidyl diphenyl phosphonate warhead for specific target protease capture, isolation and identification. Using a CDCP1-biased probe, we identify urokinase (uPA) as the master regulator of CDCP1 proteolysis, which acts both by directly cleaving CDCP1 and by activating CDCP1-cleaving plasmin. We show that coexpression of uPA and CDCP1 is strongly predictive of poor disease outcome across multiple cancers and demonstrate that uPA-mediated CDCP1 proteolysis promotes metastasis in disease-relevant preclinical in vivo models. These results highlight CDCP1 cleavage as a potential target to disrupt cancer and establish sbABP technology as a new approach to identify disease-relevant proteases.
Insights
CUB domain-containing protein 1 (CDCP1) is a cancer target. New probes identified urokinase (uPA) as a key enzyme that cleaves CDCP1, promoting cancer metastasis. Targeting this cleavage may disrupt cancer progression.
Area of Science:
- Oncology
- Proteomics
- Molecular Biology
Background:
- CUB domain-containing protein 1 (CDCP1) is an oncogenic transmembrane receptor implicated in cancer.
- Proteolytic cleavage of CDCP1 promotes cancer metastasis through poorly understood mechanisms.
Purpose of the Study:
- To rapidly identify proteases responsible for CDCP1 cleavage.
- To investigate the role of CDCP1 proteolysis in cancer metastasis.
Main Methods:
- Development and application of a substrate-biased activity-based probe (sbABP) for protease identification.
- In vivo preclinical models to assess metastasis promotion by CDCP1 proteolysis.
Main Results:
- Identified urokinase (uPA) as the master regulator of CDCP1 proteolysis.
- Demonstrated that uPA directly cleaves CDCP1 and activates plasmin for further cleavage.
- Coexpression of uPA and CDCP1 predicts poor disease outcome across multiple cancers.
- uPA-mediated CDCP1 proteolysis was shown to promote metastasis in vivo.
Conclusions:
- CDCP1 cleavage is a potential therapeutic target for cancer treatment.
- sbABP technology is a valuable tool for identifying disease-relevant proteases.
- uPA-mediated CDCP1 cleavage drives cancer metastasis.
More Related Videos
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
09:47The Determination of Protease Specificity in Mouse Tissue Extracts by MALDI-TOF Mass Spectrometry: Manipulating PH to Cause Specificity Changes
Published on: May 25, 2018